Recent Event Highlights: Genentech to Roche: We’re equipped for hard times, "Anywhere, anytime" – Genentech challenges Roche , Genentech warns board could turn hostile, Roche “not prepared to continue the existing relationship” with Genentech, Genentech wanted $112 per share from Roche; SEC filing, Genentech “disappointed” at Roche’s hostile action
Created by DNMPharma on 09/03/2009
Last updated: 11/03/10 at 17:02
Genentech believes a far-sighted approach to patent expiration, unique and life saving drugs and an unrivalled scientific culture will protect it from recession and ensure greater growth than Roche envisions.
http://www.in-pharmatechnologist.com/Industry-Drivers/Genentech-to-Roche-We-re-equipped-for-hard-times
Genentech used its investor meeting to retaliate against criticisms made by Roche, saying it will debate its financial model “anywhere, anytime with anyone”.
http://www.in-pharmatechnologist.com/Industry-Drivers/Anywhere-anytime-Genentech-challenges-Roche
As the battle for Genentech continues, the US biotech has warned its shareholders that Roche may “seek to influence our business in a manner that is contrary to our goals or strategies”.
http://www.in-pharmatechnologist.com/Industry-Drivers/Genentech-warns-board-could-turn-hostile
A filing with the SEC says that Roche is not prepared to continue in a relationship with Genentech in which it owns a majority of the biotech’s equity but has limited involvement in its governance.
http://www.in-pharmatechnologist.com/Industry-Drivers/Roche-not-prepared-to-continue-the-existing-relationship-with-Genentech
The strained relationship between Genentech and Roche has been revealed in a SEC filing, which details their differing valuations and accusations of misleading financial models.
http://www.in-pharmatechnologist.com/Industry-Drivers/Genentech-wanted-112-per-share-from-Roche-SEC-filing
Roche has stepped up its pursuit of Genentech, launching a hostile bid of $42bn after growing frustrated with the lack of progress over the past six months.
http://www.in-pharmatechnologist.com/Industry-Drivers/Genentech-disappointed-at-Roche-s-hostile-action
Genentech’s special advisory committee has rejected Roche’s $44bn offer for the biotech believing that it “substantially undervalues” the company.
http://www.in-pharmatechnologist.com/Industry-Drivers/Genentech-rejects-Roche-but-leaves-door-ajar
Roche’s proposed $44bn acquisition of Genentech is facing some opposition with Wall Street saying the offer undervalues the company, disquiet among the biotech’s employees and shareholders suing the Swiss giant.
http://www.in-pharmatechnologist.com/Industry-Drivers/Roche-faces-obstacles-in-acquiring-Genentech
Roche offered this morning to take complete control of US biotechnology giant Genentech for the princely sum of $43.7bn in a move that it says would “enhance innovation” and cut costs for both companies.
http://www.outsourcing-pharma.com/Commercial-Services/Roche-shares-dip-on-43.7bn-offer-for-Genentech
Update Sources